Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer

Japanese Journal of Clinical Oncology

Volumn 34, Issue 2, 2004, Pages 69-73

  Niho, Seiji ^a   Ohe, Yuichiro ^a   Goto, Koichi ^a   Ohmatsu, Hironobu ^a   Matsumoto, Taketoshi ^a   Kubota, Kaoru ^a   Kakinuma, Ryutaro ^a   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Febrile neutropenia; Low risk; Oral antibiotics

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTINEOPLASTIC AGENT; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; GRANULOCYTE COLONY STIMULATING FACTOR; PIPERACILLIN; PLATINUM DERIVATIVE; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LUNG CANCER; LUNG INFECTION; MALE; NAUSEA; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT INFECTION; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; FEVER; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; NEUTROPENIA; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-INFECTIVE AGENTS; CEFTAZIDIME; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 2342584203     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh019     Document Type: Article

References (12)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Rubin M, Hathorn JW, Pizzo PA. Controversies, in the management of febrile neutropenic cancer patients. Cancer Invest 1988;6:167-84.
3. Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988;148:2561-8.
4. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
5. Malik IA, Khan WA, Karim M, Aziz Z, Khan MA. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
6. Rolston KV, Rubenstein EB, Freifeld A. Early empiric antibiotic therapy for febrile neutropenia patients at low risk. Infect Dis Clin North Am 1996; 10:223-37.
7. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
8. Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305-11.
9. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341:312-8.
10. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
11. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colonystimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3559-85.
12. Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: A prospective randomised controlled single centre study. Br J Cancer 2003;89:43-9.